Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)

Basit Öğe Kaydı
dc.contributor.authorTuncer, Aslı
dc.contributor.authorKürtüncü, Murat
dc.contributor.authorTerzi, Murat
dc.contributor.authorUygunoğlu, Uğur
dc.contributor.authorGöncüoğlu, Cansu
dc.contributor.authorYüceyar, Ayşe Nur
dc.contributor.authorEkmekçi, Özgül
dc.contributor.authorTürkoğlu, Recai
dc.contributor.authorSoysal, Aysun
dc.contributor.authorKöseoğlu, Mesrure
dc.contributor.authorBoz, Cavit
dc.contributor.authorBeckmann, Yeşim
dc.date.accessioned2023-03-14T09:30:15Z
dc.date.available2023-03-14T09:30:15Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nöroloji Ana Bilim Dalı
dc.description.abstractBackground/aim: During multiple sclerosis (MS) treatment different modes of action such as lateral (interferon beta to glatiramer acetate or glatiramer acetate to interferon beta) or vertical (interferon beta/glatiramer acetate to fingolimod) drug switch can be performed. This study aims to investigate the clinical effectiveness of switching from the first-line injectable disease modifying treatments (iDMTs) to fingolimod (FNG) compared to switching between first-line iDMTs. Materials and methods: This is a multicenter, observational and retrospective study of patients with relapsing-remitting MS who had lateral and vertical switch. The observation period included three key assessment time points (before the switch, at switch, and after the switch). Data were collected from the MS patients’ database by neurologists between January 2018 and June 2019. The longest follow-up period of the patients was determined as 24 months after the switch. Results: In 462 MS patients that were included in the study, both treatments significantly decreased the number of relapses during the postswitch 12 months versus preswitch one year while patients in the FNG group experienced significantly fewer relapses compared to iDMT cohort in the postswitch 12 months period. FNG cohort experienced fewer relapses than in the iDMT cohort within the postswitch 2 year. The mean time to first relapse after the switch was significantly longer in the FNG group. Conclusion: The present study revealed superior effectiveness of vertical switch over lateral switch regarding the improvement in relapse outcomes. Patients in the FNG cohort experienced sustainably fewer relapses during the follow-up period after the switch compared the iDMT cohort. Importantly, switching to FNG was more effective in delaying time to first relapse when compared with iDMTs.
dc.identifier.citationTuncer, A., Kürtüncü, M., Terzi, M., Uygunoğlu, U., Göncüoğlu, C., Yüceyar, A. N. ... Beckmann, Y. (2023). Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE). Turkish Journal of Medical Sciences, 53(1), 323-332. https://dx.doi.org/10.55730/1300-0144.5588
dc.identifier.doi10.55730/1300-0144.5588
dc.identifier.endpage332
dc.identifier.issn1300-0144
dc.identifier.issue1
dc.identifier.scopus2-s2.0-85149131178
dc.identifier.scopusqualityQ3
dc.identifier.startpage323
dc.identifier.urihttps://dx.doi.org/10.55730/1300-0144.5588
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10614
dc.identifier.volume53
dc.identifier.wos000941667500038en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorBirday, Erkingül
dc.language.isoen
dc.publisherTurkiye Klinikleri
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBeta Interferon
dc.subjectDisease Modifying Treatment
dc.subjectFingolimod
dc.subjectGlatiramer Acetate
dc.subjectTreatment Switch
dc.titleRetrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu